Clinical trial · Observational
An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer
NCT01860144CI-TRIAL-00017945unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational, multicenter, prospective study will evaluate the use of bevacizumab in real clinical practice in chinese patients with metastatic colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- bevacizumab
- description
- Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
- interventionNames
- Drug: Bevacizumab
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- 6 weeks
- description
- To evaluate the treatment response of bevacizumab in Chinese patients with mCRC in real clinical practice
Secondary outcomes (4)
- measure
- overall survival
- timeFrame
- 3 months
- description
- OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 3 months till death or lost
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed metastatic colorectal cancer patients Having initiated treatment with bevacizumab Exclusion Criteria: * non-metastatic colorectal cancer patients not recieved bevacizumab
References
Publications (0)
Data not yet available
No reference posted for this study.